Caption Management, LLC Arvinas, Inc. Call Options Transaction History

Caption Management, LLC

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$23.66 - $32.73 $99,372 - $137,466	4,200 Added 10.5%	44,200 $1.09 Million
Q2 2024 Aug 14, 2024	BUY	$24.46 - $40.4 $978,400 - $1.62 Million	40,000 New	40,000 $1.06 Million
Q3 2022 Nov 14, 2022	SELL	$41.87 - $57.99 $4.87 Million - $6.74 Million	-116,200 Reduced 44.27%	146,300 $6.51 Million
Q2 2022 Aug 15, 2022	BUY	$36.01 - $74.24 $3.69 Million - $7.61 Million	102,500 Added 64.06%	262,500 $11 Million
Q4 2021 Feb 11, 2022	BUY	$65.85 - $96.21 $10.5 Million - $15.4 Million	160,000 New	160,000 $13.1 Million
Q2 2021 Aug 16, 2021	SELL	$60.45 - $84.26 $4.9 Million - $6.83 Million	-81,000 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$58.19 - $91.37 $3.4 Million - $5.35 Million	58,500 Added 260.0%	81,000 $5.36 Million
Q2 2020 Aug 14, 2020	BUY	$29.88 - $56.74 $672,300 - $1.28 Million	22,500 New	22,500 $755,000
Q1 2020 May 15, 2020	SELL	$33.0 - $54.5 $825,000 - $1.36 Million	-25,000 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$15.39 - $44.38 $384,750 - $1.11 Million	25,000 New	25,000 $1.03 Million

229

68.4M

226K

285K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $997M
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Caption Management, LLC with notifications on news.